Published on 22 Dec 2023 on Zacks via Yahoo Finance
Sanofi (SNY) Discontinues Tusamitamab Ravtansine Cancer Program
Sanofi SNY announced that it is ending the development of the cancer program called tusamitamab ravtansine based on the outcome of a prespecified interim analysis conducted by an Independent Data Monitoring Committee (IDMC).
The CARMEN-LC03 study investigated tusamitamab ravtansine, a type of an antibody-drug conjugate, as a monotherapy compared to docetaxel in previously treated patients with metastatic non-squamous non-small cell lung cancer whose tumors express high levels of carcinoembryonic antigen-related cell adhesion molecule 5.
The CARMEN-LC03 study had dual primary endpoints – progression-free survival (PFS) and overall survival (OS).